Enoxaparin-metformin and enoxaparin alone may safely reduce pregnancy loss (Q46187383)

20 December 2017

title

Enoxaparin-metformin and enoxaparin alone may safely reduce pregnancy loss (English)

1 reference

20 December 2017

0 references

1 reference

3

1 reference

20 December 2017

author name string

Ganga Ramidi

1

1 reference

20 December 2017

Naseer Khan

2

1 reference

20 December 2017

Ping Wang

4

1 reference

20 December 2017

Naila Goldenberg

5

1 reference

20 December 2017

publication date

4 December 2008

1 reference

20 December 2017

published in

Translational Research

1 reference

20 December 2017

volume

153

1 reference

20 December 2017

issue

1

1 reference

20 December 2017

page(s)

33-43

1 reference

20 December 2017

Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Effects of metformin on early pregnancy loss in the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Metformin reduces abortion in pregnant women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Relationship between abnormal glucose tolerance test and history of previous recurrent miscarriages, and beneficial effect of metformin in these patients: a prospective clinical study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Factor V Leiden mutation as a risk factor for recurrent pregnancy loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Recurrent miscarriage syndrome due to blood coagulation protein/platelet defects: prevalence, treatment and outcome results. DRW Metroplex Recurrent Miscarriage Syndrome Cooperative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Inherited thrombophilia and poor pregnancy outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Thrombophilia and pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

High prevalence of the prothrombin gene mutation in women with intrauterine growth retardation, abruptio placentae and second trimester loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Inherited Thrombophilia and Gestational Vascular Complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Increased frequency of genetic thrombophilia in women with complications of pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Mid-trimester severe intrauterine growth restriction is associated with a high prevalence of thrombophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Genetic hypofibrinolysis in complicated pregnancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Thrombophilia and its treatment in pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Factor V Leiden mutation: a treatable etiology for sporadic and recurrent pregnancy loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Third-trimester unexplained intrauterine fetal death is associated with inherited thrombophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Thrombophilic disorders and fetal loss: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

The effect of thrombophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Recurrent pregnancy loss: summary and clinical recommendations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

The long and winding road ... towards LMWH for pregnancy loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

A protocol for the use of enoxaparin during pregnancy: results from 85 pregnancies including 13 multiple gestation pregnancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Inherited thrombophilia: treatment during pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Antithrombotic prophylaxis during pregnancy in women with deficiency of natural anticoagulants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Are women with polycystic ovary syndrome resistant to activated protein C?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Polycystic ovarian syndrome and thrombophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Low-molecular-weight heparin for thrombophilia in pregnant women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the Live-Enox study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Preferential X-chromosome inactivation in women with idiopathic recurrent pregnancy loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Immunoglobulin A anti-beta2-glycoprotein antibodies in women who experience unexplained recurrent spontaneous abortion and unexplained fetal death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Cytokine promoter gene polymorphisms and idiopathic recurrent pregnancy loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughou

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

A prospective analysis of the HOMA model. The Mexico City Diabetes Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: an independent risk factor for serious pregnancy complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Polymorphisms in the ACE and PAI-1 genes are associated with recurrent spontaneous miscarriages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Prevalence and Trends in Obesity Among US Adults, 1999-2000

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Polycystic ovary syndrome, the G1691A factor V Leiden mutation, and plasminogen activator inhibitor activity: associations with recurrent pregnancy loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Recurrent fetal aneuploidy and recurrent miscarriage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Parental karyotype and subsequent live births in recurrent miscarriage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Is miscarriage a coagulopathy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Thrombophilia-associated pregnancy wastage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Factor V Leiden and recurrent miscarriage-prospective outcome of untreated pregnancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

inferred from DOI database lookup

7 January 2021

based on heuristic

Activated protein C resistance and factor V Leiden mutation can be associated with first-as well as second-trimester recurrent pregnancy loss.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Low-molecular-weight heparin during pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

Hypofibrinolysis, thrombophilia, osteonecrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.11.003

10.1016/J.TRSL.2008.11.003

7 January 2021

Identifiers

DOI

1 reference

20 December 2017

1 reference

20 December 2017